Posted by Michael Wonder on 05 Feb 2026
Oncolytics Biotech receives FDA fast track designation for pelareorep in second-line KRAS mutant MSS metastatic colorectal cancer
4 February 2026 - Pelareorep now has fast track designation for two gastro-intestinal cancers, solidifying its potential as an immunotherapeutic platform therapy in gastro-intestinal cancers.
Oncolytics Biotech today announced that the US FDA has granted fast track designation to pelareorep in combination with bevacizumab (Avastin) and leucovorin, fluorouracil, irinotecan (FOLFIRI) for the treatment of patients with KRAS mutant, microsatellite stable metastatic colorectal cancer in the second-line setting.
